Styrax Pharma is an API manufacturer based in India. It holds 2 active US drug master files and 2 valid CEPs across a filed portfolio of 4 molecules. Customs aggregates show $543K of exports covering 17 molecules to 6 destinations in 2025.
| Site | FDA FEI |
|---|---|
| Visakhapatnam, India | Not on file |
| Anakapalli, India | 3014406503 |
| Molecule | Regulators | Docs |
|---|---|---|
| Allopurinol | EDQM | 1 |
| Dolutegravir | US FDA | 1 |
| Itraconazole | EDQM | 1 |
| Tenofovir Disoproxil | US FDA | 1 |
Also appears on these molecule pages
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $5K | 1 |
| 2025 | Not reported | $543K | 6 |
| 2024 | Not reported | $161K | 6 |
| 2023 | Not reported | $827K | 4 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Styrax Pharma comes back tiered against every other supplier able to file there.
Start for free